Juliet Moritz

For years, Duchenne muscular dystrophy drug trials included a specific endpoint requiring that they enroll only patients who were still able to walk. That changed when a DMD-focused advocacy organization took the matter up with the FDA and helped develop new trial guidelines.

Patient advocates are witnessing a shift in the culture of drug development as sponsors and regulatory agencies show more interest in incorporating patient perspectives.